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ABSTRACT
INTRODUCTION Currently, around 35–80% of patients undergoing cardiac surgery in the UK receive a blood transfusion. Ret-
rograde autologous priming (RAP) of the cardiopulmonary bypass circuit has been suggested as a possible strategy to reduce 
blood transfusion during cardiac surgery.
METHODS Data from 101 consecutive patients undergoing isolated coronary artery bypass grafts (where RAP was used) were 
collected prospectively and compared with 92 historic patients prior to RAP use in our centre.
RESULTS Baseline characteristics (ie age, preoperative haemoglobin [Hb] etc) were not significantly different between the 
RAP and non-RAP groups. The mean pump priming volume of 1,013ml in the RAP group was significantly lower (p<0.001) 
than that of 2,450ml in the non-RAP group. The mean Hb level at initiation of bypass of 9.1g/dl in patients having RAP was 
significantly higher (p<0.001) than that of 7.7g/dl in those who did not have RAP. There was no significant difference between 
the RAP and non-RAP groups in transfusion of red cells, platelets and fresh frozen plasma, 30-day mortality, re-exploration 
rate and predischarge Hb level. The median durations of cardiac intensive care unit stay and in-hospital stay of 1 day (inter-
quartile range [IQR]: 1–2 days) and 5 days (IQR: 4–6 days) in the RAP group were significantly shorter than those of the non-
RAP group (2 days [IQR: 1–3 days] and 6 days [IQR: 5–9 days]).
CONCLUSIONS In the population group studied, RAP did not influence blood transfusion rates but was associated with a 
reduction in duration of hospital stay.
Postoperative blood loss and anaemia in surgical patients is 
a major concern for the surgeon as the former reduces the 
body’s ability to sustain adequate perfusion of the essential 
organs and is associated with significant postoperative com-
plications such as renal failure, cerebral events and cardiac 
ischaemia. However, the treatment in the form of allogenic 
blood and blood products has its own inherent risks includ-
ing ABO incompatibility along with other antibody antigen 
reactions (1:10,000), blood borne infections (1:350,000), 
risk of transfusion-related acute lung injury (1:5,000), brain 
oedema, renal impairment (around 2%), and the rarer graft 
versus host syndromes, all of which are devastating to a 
patient’s recovery.1 There are also issues for some patients 
regarding religious belief and the use of exogenous blood, 
which limit treatment options for such patients following 
significant blood loss.
Haemodilution influences the physiological oxygen car-
rying capability. Despite this, the first response employed to 
manage significant blood loss both intra and postoperatively 
is often the instillation of colloid or crystalloid solution to 
expand the patient’s plasma volume, a practice that causes 
further haemodilution.
Standard priming techniques of the bypass circuit 
involve the use of crystalloid solutions such as Hartmann’s, 
which are ‘dumped’ into the patient’s circulation. The 
volumes of this solution can be in the region of 2,000ml. In 
addition to the potential 900ml of blood lost, this can over-
whelm the body’s capacity to maintain homeostasis. Some 
of the measures (apart from blood donation) employed 
to reduce the amount of haemodilution intraoperatively 
include acute normovolaemic haemodilution, cell 
salvage procedures and homological agents, all of 
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which are used to maintain haemoglobin (Hb) 
concentrations.
The above measures are all used in our unit along with 
retrograde autologous priming (RAP) of the cardiopul-
monary bypass (CPB) unit in order to limit the amount of 
haemodilution caused. This process uses the patient’s own 
blood to prime the bypass machine. The main hypothesis of 
this study was that RAP actually has an impact on the need 
for blood transfusion in coronary artery bypass grafting 
(CABG). Furthermore, the effect of RAP on length of cardiac 
intensive care unit stay, length of hospital stay, morbidity 
and mortality was also assessed.
methods
Overall, 193 patients undergoing first-time, isolated CABG 
where the CPB machine was used (on pump) were includ-
ed in this study. Data were collected prospectively on 101 
consecutive patients who underwent RAP (study cohort) and 
92 historic patients (consecutive patients who underwent 
surgery within three months prior to institution of RAP) who 
underwent non-RAP isolated CABG (control group). Data 
were collected preoperatively and intraoperatively, and 
included measurements of Hb preoperatively, on-CPB and 
prior to discharge. A similar dataset for the non-RAP group 
was retrieved from a prospectively collected database. 
Exclusion criteria included all non-CABG operations, any 
operation that was a combined valve and CABG proce-
dure, and all off-pump CABG operations as well as primary 
operations that were due to complication. Post/intraop-
erative data included the need for blood and products 
transfusion, postoperative complications (atrial fibrillation, 
infection, renal dysfunction, need for re-exploration), car-
diac intensive care unit and in-hospital stay, and mortality.
There was no change in clinical practice during that 
period although our unit did not have a defined care 
pathway at the time of the study. The transfusion trigger 
remained at a Hb level of ≤8g/dl as measured on the 
arterial blood gas on the intensive care unit. The amount of 
blood product given to each patient was determined by 
assessment of coagulation by thromboelastography and/
or a recent history (≤5 days) of intake of antiplatelet agent 
(aspirin, clopidogrel). All patients in both groups received 
tranexamic acid starting prior to skin incision (3–5g). 
Anaesthesia was with propofol and isoflurane 
intraoperatively, and propofol and morphine post-
operatively. Patients were extubated if they 
were not bleeding, were warm and responded 
Table 1 Preoperative patient characteristics
RAP (n=101) Control (n=92) p-value
Mean age 65.6 yrs (SD: 9.7 yrs) 65.5 yrs (SD: 8.4 yrs) 0.9
Mean EuroSCORE 3.9 (SD: 2.6) 3.7 (SD: 2.6) 0.4
Male patients 91% 83% 0.08
Elective 58% 69% 0.1
Impaired LV 31% 41% 0.3 
RAP = retrograde autologous priming; SD = standard deviation; LV = left ventricular function
Table 2 Postoperative data
RAP (n=101) Control (n=92) p-value
Mean CPB prime volume 1,013ml (SD: 189ml) 2,450ml (SD: 484ml) <0.001
Mean Hb on CPB 9.1g/dl (SD: 1.4g/dl) 7.8g/dl (SD: 1.4g/dl) <0.001
Mean CPB time 86 mins (SD: 27 mins) 80 mins (SD: 30 mins) 0.1
Blood transfusion 36% 40% 0.3
Platelet transfusion 15% 13% 0.4
FFP transfusion 4% 9% 0.09
Re-exploration for bleeding 4% 7% 0.2
Atrial fibrillation 24% 26% 0.5
Infections 12% 11% 0.5
Renal dysfunction 4% 5% 0.4
30-day mortality rate 2% 3% 0.5 
RAP = retrograde autologous priming; CPB = cardiopulmonary bypass; SD = standard deviation; Hb = haemoglobin; FFP = fresh frozen plasma
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appropriately on command after withdrawal of propofol, 
and no patients in the study failed the RAP process.
CPB Hb refers to the first Hb level once CPB was estab-
lished. Patients were not transfused during the CPB run. Six 
surgeons were included in this study. Statistical analysis 
was performed using SSPS® version 10 (SPSS, Chcago, IL, 
US), and included the chi-squared test (nominal data) and 
Mann–Whitney U test or Wilcoxon signed-rank test (interval 
data). A p-value of <0.05 was considered significant.
Results
Table 1 highlights that baseline characteristics were not 
significantly different between the RAP and non-RAP 
groups. The mean preoperative Hb levels were 13.5g/dl 
(standard deviation [SD]: 1.6g/dl) and 13.9g/dl (SD: 1.3g/dl) 
respectively (p=0.1). However, the mean pump prim-
ing volume in the RAP group (1,013ml [SD: 189ml]) was 
significantly lower than that of the non-RAP group (2,450ml 
[SD: 484ml]).
Despite this divergence, there was no significant differ-
ence between the RAP and non-RAP groups in transfusion 
rates of red cells, platelets and fresh frozen plasma, 30-day 
mortality, re-exploration rates, incidence of postopera-
tive atrial fibrillation and predischarge Hb levels (Table 2). 
Nevertheless, the median durations of cardiac inten-
sive care unit stay and in-hospital stay were significantly 
shorter in the RAP group (1 day, interquartile range [IQR]: 
1–2 days; and 5 days, IQR: 4–6 days respectively) than in the 
non-RAP group (1 day, IQR: 1–3 days; and 6 days, IQR: 5–9 
days respectively). Moreover, while on bypass, the degree 
of haemodilution (as judged by the first on-CPB Hb levels) 
was much less in the RAP group (p<0.001). There were no 
reported incidents during the RAP process.
Discussion
Over the past decade, many surgical and non-surgical 
methods have been developed to reduce the need for blood 
and blood products in cardiothoracic surgery. One of these 
was the development of RAP of the CPB circuit technique. 
The evidence pertaining to this technique is scanty at best, 
with only six randomised controlled trials2–7 published 
surrounding the topic, all of which were considered in a 
meta-analysis8 to be of low value on the Jadad scale, a 
scoring system to determine the quality of a study from an 
evidence standpoint.9
There are no existing guidelines from the National 
Institute for Health and Clinical Excellence related to 
the practice of RAP so current practice is variable. One 
study of over 10,000 patients in 70 cardiothoracic centres 
estimated that the average blood loss per patient was 
917ml10 and other similar studies show the rates of blood 
transfusion around 86%.11 This shows the need for effective 
blood conserving practices.
The meta-analysis8 of the six randomised controlled 
trials2–7 investigating RAP showed a 64% reduction (odds 
ratio [OR]: 0.36, 95% confidence interval [CI]: 0.13–0.94, 
p=0.04) in the need for the use of blood intraoperatively and 
a 74% reduction (OR: 0.26, 95% CI: 0.13–0.52, p=0.0001) in 
the need for blood during a hospital stay. The mean intra-
operative fluid balance was not significantly different in 
RAP patients (1,574.6ml) compared with the control groups 
(2,016.2ml) (p=0.44). The majority of these patients un-
derwent primary CABG although other procedures were 
represented in the studies at a smaller proportion.
Information included in the meta-analysis seems to 
question the robustness of clinical benefit when RAP 
is used. This conclusion is derived from the sensitivity 
analysis of the data in the six trials and the outcome is also 
reinforced when a retrospective trial of the largest series in the 
group is scrutinised. That study concluded that there was no 
clinical effectiveness in the use of RAP.12
Our study showed that there was a significant difference 
in pump priming volumes, which is to be expected when 
comparing a RAP with a non-RAP procedure, but there was 
no difference in transfusion rate between RAP and non-RAP 
patients. Interestingly, there was a significant difference 
in the on-CPB Hb levels (RAP 9.1g/dl vs non-RAP 7.7g/dl, 
p<0.001), which may confer an advantage in postoperative 
recovery to the RAP group. The fact that both groups had 
similar transfusion rates postoperatively and similar Hb 
levels at discharge would suggest that the body’s homeostat-
ic properties came into play and allowed for some degree of 
haemoconcentration.
With regard to patient safety, our study indicates 
that RAP is as safe as non-RAP as there were no reported 
incidents during the RAP process. Furthermore, there 
was no difference in 30-day mortality, the need for re- 
exploration, fresh frozen plasma/platelets transfusion and 
predischarge Hb levels. Nevertheless, further study is 
needed to determine a full safety profile.
There was a significantly shorter length of cardiac 
intensive care unit stay and total hospital stay for the RAP 
group. A shorter hospital stay has potentially beneficial 
financial implications as well as increasing patient safe-
ty by reducing exposure to hospital acquired infection. 
Unfortunately, whether the shorter length of stay was due 
solely to the use of RAP could not be elucidated by the 
current study.
Conclusions
This study confirmed that RAP is likely to be safe but 
did not influence postoperative blood transfusion rates. 
However, there was a shorter in-hospital stay in the RAP 
group. A large randomised controlled trial that includes a 
more detailed observation of the pre, intra and postoperative 
Hb measurements as well as the immediate and day 1 Hb 
levels is needed. Furthermore, a robust cost–benefit 
analysis may be required to elucidate the full benefits of RAP 
from a financial perspective.
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